Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04913025
Title REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications

melanoma

renal cell carcinoma

Advanced Solid Tumor

Therapies

Pembrolizumab

Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.